Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 8/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44919 | 0.91 | SLC34A2 (0.57) | SLC34A2F10ACKR3 | |
| SCHEMBL44920 | 0.91 | SLC34A2 (0.57) | SLC34A2F10ACKR3 | |
| SCHEMBL267754 | 0.90 | SLC34A2 (0.65) | SLC34A2F10ACKR3 | |
| SCHEMBL274012 | 0.90 | SLC34A2 (0.65) | SLC34A2F10ACKR3 | |
| SCHEMBL267755 | 0.90 | SLC34A2 (0.65) | SLC34A2F10ACKR3 | |
| SCHEMBL46623 | 0.87 | SLC34A2 (0.49) | SLC34A2ALDH1A1 | |
| SCHEMBL267928 | 0.86 | SLC34A2 (0.53) | SLC34A2MAPT | |
| SCHEMBL274314 | 0.86 | SLC34A2 (0.53) | SLC34A2MAPT | |
| SCHEMBL267927 | 0.86 | SLC34A2 (0.53) | SLC34A2MAPT | |
| SCHEMBL45091 | 0.85 | SLC34A2 (0.49) | SLC34A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | SLC34A2 2/4885F10 1866/4885KDM4E 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.